康缘药业：泻白散颗粒获药品注册证书

Core Viewpoint - Kangyuan Pharmaceutical (600557) has recently received a drug registration certificate for Xiebaisan granules from the National Medical Products Administration, indicating a significant regulatory approval for the company’s product aimed at treating pediatric cough and asthma due to lung heat [1] Group 1 - The drug Xiebaisan is indicated for clearing lung heat and alleviating cough and asthma symptoms in children [1] - The approval of the drug registration certificate represents a milestone for Kangyuan Pharmaceutical, potentially enhancing its product portfolio and market presence [1]